TM
MIRM icon

Torren Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Torren Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8
Closed -$632 – 1258
2025
Q4 		$632 Buy
+8
New +$574 ﹤0.01% 1293

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Torren Management's MIRM Position: Q1 2026 in Review

Torren Management sold out of Mirum Pharmaceuticals (MIRM) in Q1 2026, closing a stake of 8 shares — an estimated $632 sold.

Torren Management first reported a position in MIRM in Q4 2025 and held it in 1 quarter. The position peaked at $632 in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Torren Management reported no remaining Mirum Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Torren Management sold 8 Mirum Pharmaceuticals shares in Q1 2026, an estimated $632.
  • Torren Management first reported a position in Mirum Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Torren Management's Mirum Pharmaceuticals position peaked at $632 in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.